Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), today announced that the first patient has been enrolled in the quadruple-blinded sham-controlled AIM HIGHer IDE clinical study (Assessment of Implantable CCM in the Heart Failure Group with Higher Ejection Fraction) evaluating CCM therapy for patients who have left ventricular ejection fraction ranging between 40% and 60% inclusive. The study will be conducted across approximately 150 cente
News | Heart Failure
Impulse Dynamics Announces First Patient Enrolled in AIM HIGHer Study

April 4, 2022 – Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart ...

Home April 04, 2022
Home
Nexletol logo
News | ACC
Esperion Announces Two NEXLETOL Data Presentations at ACC.22
April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...
Home April 04, 2022
Home
Significant VHD is commonly encountered in practice, more commonly with advancing age, among women, and identified more frequently in centers offering percutaneous mitral therapies.
News | ACC
egnite, Inc. Announces Data from the Largest Contemporary Analysis of Valvular Heart Disease Prevalence in the US

April 3, 2022 — egnite, Inc., an advanced technology digital health company focused on providing artificial intelligence ...

Home April 03, 2022
Home
A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C.
News | ACC
ACC22: Interim Findings Show Promise in Decreasing Shortness of Breath From Hypertrophic Cardiomyopathy

April 3, 2022 — A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath ...

Home April 03, 2022
Home
Silence Therapeutics, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today presented detailed results from its phase 1 APOLLO trial
News | Heart Failure
Silence Therapeutics Announces Detailed Results from SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at ACC22

April 3, 2022 — Silence Therapeutics, a leader in the discovery, development and delivery of novel short interfering ...

Home April 03, 2022
Home
Aidoc, a leading provider of healthcare AI solutions, announced that it received FDA 510(k) clearance for its triage and notification of pneumothorax on X-ray exams.
News | Artificial Intelligence
Aidoc Expands AI Service to X-ray, Receiving FDA 510(k) Clearance for Pneumothorax

April 2, 2022 — Aidoc, a leading provider of healthcare AI solutions, announced that it received FDA 510(k) clearance ...

Home April 02, 2022
Home
Royal Philips, a global leader in health technology, today announced the launch of Ultrasound Workspace [OLK1] at the American College of Cardiology’s Annual Scientific Session & Expo (ACC 2022).
News | Cardiovascular Ultrasound
Philips Launches Ultrasound Workspace at ACC 2022

April 2, 2022 — Royal Philips, a global leader in health technology, today announced the launch of Ultrasound Workspace ...

Home April 02, 2022
Home
New ACC/AHA/HFSA guideline redefines heart failure stages to focus on prevention, updates treatment options and emphasizes care coordination with a heart failure specialty team
News | Heart Failure
ACC, AHA, HFSA Issue Joint Heart Failure Guideline

April 1, 2022 — A new joint guideline published today from the American College of Cardiology, the American Heart ...

Home April 01, 2022
Home
The poster titled “Short term prediction of Atrial Fibrillation from ambulatory ECG using deep learning” presents results of a clinical study demonstrating that Cardiologs’ AI algorithm can predict the short-term risk of atrial fibrillation (AFib) based on single-lead Ambulatory electrocardiograms (ECGs) that show normal sinus rhythm.
News | Atrial Fibrillation
Cardiologs Announces Poster Presentation at ACC 2022

April 1, 2022 — Cardiologs announced a poster presentation at the 2022 American College of Cardiology (ACC) meeting in ...

Home April 01, 2022
Home
Philips Ambient Experience with FlexVision display for pediatric patients
News | ACC
Philips Adds to its Cardiology Suite of Solutions at ACC 2022

April 1, 2022 — Royal Philips, a global leader in health technology, announced new additions to its innovative ...

Home April 01, 2022
Home
Screen Shot 2022-02-11 at 10.29.50 AM_0
News | ACC
Aidoc Showcases Full Cardiovascular AI Care Coordination Suite at ACC.22
March 31, 2022 – Healthcare AI solutions provider Aidoc will be delivering a live demonstration of its comprehensive AI ...
Home March 31, 2022
Home
800_gettyimages-1318375532
News | ACC
ACC Scientific Session 2022 to Feature Smidt Heart Institute Experts
March 31, 2022 – Experts from the Smidt Heart Institute at Cedars-Sinai, home to California’s top-ranked cardiology and ...
Home March 31, 2022
Home
CathWorks_PressReleaseCard__V2
News | ACC
CathWorks Presents New Data and Latest Innovations at ACC 2022
March 31, 2022 – CathWorks has announced that the results of its most recent outcomes study on the CathWorks FFRangio ...
Home March 31, 2022
Home
In accordance with its commitment to patient safety, Medtronic recently voluntarily recalled a subset of its IN.PACT Admiral and IN.PACT AV Paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) balloon catheters due to the potential for pouch damage resulting in a loss of sterility.
News | Drug-Eluting Balloons
Medtronic Issues Voluntary Recall for Subset of IN.PACT Admiral and IN.PACT AV Drug Coated Balloon

March 31, 2022 — In accordance with its commitment to patient safety, Medtronic recently voluntarily recalled a subset ...

Home March 31, 2022
Home
MedWatch, The FDA Safety Information and Adverse Event Reporting Program, announced that Pfizer is recalling Accuretic (quinapril hydrochloride/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril HCL and hydrochlorothiazide and quinapril HCl/hydrochlorothiazide) due to the presence of a nitrosamine, N-nitroso-quinapril, above the Acceptable Daily Intake level.
Feature | Cardiovascular Business | By Melinda Taschetta-Millane
Top 10: Most Read Cardiology Content in March 2022

Here is what you and your colleagues found to be most interesting in the field of cardiology during the month of March ...

Home March 31, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now